About Us
siRNAgen uses a no-formulation conjugate micellar siRNA platform, SAMiRNA, to develop transformative therapies for chronic conditions.
siRNAgen Therapeutics, a platform products company, was founded in 2019 as a spinout from Bioneer, one of the world's major oligo manufacturers. The platform was developed based on 20 years of research by Bioneer's leading oligo researchers.
SAMiRNA simplifies siRNA therapies using modular chemistry and self-assembly to enable delivery to target tissues.
SAMiRNA platform enables the delivery of siRNA to organs that are difficult to reach, like the brain. The modular design of the double conjugate RNAi design offers significant versatility, covering a breadth of indication areas thanks to the tunable targetability and the flexible routes of administration.
Today, siRNAgen has cross-border operations in the US and Korea with a team of 26 employees, 40% of which are Ph.D.'s. The current platforms in development include SAMiRNA and GLUT-SAMiRNA, and therapeutic areas are in inflammatory/fibrosis and CNS indications. Our lead asset, SRN-001, is an anti-inflammatory and fibrosis RNAi therapeutic targeted for Phase 1a in 2023.